Background Off-label prescribing is prevalent in healthcare. There is a lack of understanding of pharmacists’ attitudes toward the practice of off-label prescribing, especially those that are prescribed for other indications than approved ones (termed as indication-based off-label prescribing). Objective Explore hospital pharmacists’ attitudes toward and perceived responsibility in off-label and indication-based off-label prescribing in hospital pharmacy practice. Setting Pharmacists practicing in hospitals in the United States were investigated. Method Pharmacists were contacted via email through State affiliates of the American Society of Health-System Pharmacist. The survey described an indication-based off-label medication order for a hospitalized patient and the prescribing physician. Data were collected via Qualtrics. Main outcome measure Questions focused on awareness, beliefs, and responsibility—including, risk assessment and monitoring outcomes—related to off-label and indication-based offlabel prescribing. Results Of 107 pharmacist respondents, about 79% and 98% reported being familiar with offlabel and indication-based off-label prescribing, respectively. While 77.6% pharmacists believed that patients should be informed, only 37.4% agreed that they had responsibility of informing physicians; presence of policy was associated (p < 0.02) with pharmacist agreeing to inform physicians. Over 70% agreed that patients should be closely monitored for outcomes and 43.1% believed physicians had predominant responsibility of monitoring outcomes. Conclusion Pharmacists’ perceived responsibility and beliefs regarding off-label prescribing are insightful that can be utilized for improving patient care.
Attitudes Hospital pharmacists Off-label prescribing Pharmacy practice Responsibility United States
This is a preview of subscription content, log in to check access.
This study did not receive any funding.
Conflicts of interest
The authors declare that they have no competing interests.
Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt KG, Läer S. Off-label drug use among hospitalised children: identifying areas with the highest need for research. Pharm World Sci. 2008;30(5):497–502.CrossRefPubMedGoogle Scholar
Chalumeau M, Tréluyer JM, Salanave B, Assathiany R, Chéron G, Crocheton N, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child. 2000;83:502–5.CrossRefPubMedPubMedCentralGoogle Scholar
Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M. Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr. 2002;91:339–47.CrossRefPubMedGoogle Scholar
Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker BH, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002;58:293–7.CrossRefPubMedGoogle Scholar
Bajcetic M, Jelisavcic M, Mitrovic J, Divac N, Simeunovic S, Samardzic R, et al. Off label and unlicensed drugs use in paediatric cardiology. Eur J Clin Pharmacol. 2005;61:775–9.CrossRefPubMedGoogle Scholar
Graziul C, Gibbons R, Alexander GC. Association between the commercial characteristics of psychotropic drugs and their off-label use. Med Care. 2012;50(11):940–7.CrossRefPubMedGoogle Scholar
Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, et al. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res. 2008;58(5–6):316–22.CrossRefPubMedGoogle Scholar
Ekins-Daukes S, Helms PJ, Taylor MW, McLay JS. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol. 2005;60(2):145–9.CrossRefPubMedPubMedCentralGoogle Scholar
Mukattash T, Hawwa AF, Trew K, McElnay JC. Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol. 2011;67:449–61.CrossRefPubMedGoogle Scholar
Stewart D, Rouf A, Snaith A, Elliott K, Helms PJ, McLay JS. Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey. Br J Clin Pharmacol. 2007;64:90–5.CrossRefPubMedPubMedCentralGoogle Scholar
Ansani N, Branch R, Fedutes-Henderson B, Smitherman T, Weber RJ, Skledar S, et al. Unites States medical practice summary Innovative off-label medication use. Am J Med Qual. 2006;21:246–54.CrossRefPubMedGoogle Scholar
Lenk C, Koch P, Zappel H, Wiesemann C. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics. Eur J Pediatr. 2009;168:1473–8.CrossRefPubMedPubMedCentralGoogle Scholar
Bertsche T, Hammerlein A, Schulz M. German national drug information service: user satisfaction and potential positive patient outcomes. Pharm World Sci. 2007;29:167–72.CrossRefPubMedGoogle Scholar
Sellors J, Kaczorowski J, Sellors C, Dolovich L, Woodward C, Willan A, et al. A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ. 2003;169:17–22.PubMedPubMedCentralGoogle Scholar
Choonara I. Unlicensed and off-label drug use in children: implications for safety. Exp Opin Drug Saf. 2004;3:81–3.CrossRefGoogle Scholar
Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs Medical Center. Am J Health Syst Pharm. 2002;59:2070–7.PubMedGoogle Scholar
Basak R, Bentley JP, McCaffrey DJ III, Bouldin AS, Banahan BF III. The role of perceived impact on relationship quality in pharmacists’ willingness to influence indication-based off-label prescribing decisions. Soc Sci Med. 2015;132:181–9.CrossRefPubMedGoogle Scholar